Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ORCHPHARMA

ORCHPHARMA

HealthcarePharmaceuticals & Biotechnology₹5721 cr market cap
₹948.60 ▼ -0.77% today As of 19 Nov 2026
52-week low ₹482.4552-week high ₹1107.20

-13.7% from the 52-week high · +98.1% above the low

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

The short version. ORCHPHARMA reported revenue of ₹341 crore for Sep 2026, up 75.8% from a year earlier. Net profit was ₹29 crore. Return on equity was 0.6% in Mar 2026. Promoter holding was 74.45% in Sep 2026, up 4.61 points over 8 quarters.

1 · The price

How has the stock traded?

ORCHPHARMA trades 13.7% below its 52-week high and 98.1% above its 52-week low.

Change over period: —

1M+7.0%
3M-2.4%
6M+33.6%
1Y+13.5%

2 · The business

Is it growing?

Sales, year on year+75.8%

Sep 2026 revenue of ₹341 cr.

Net margin8.4%

11.4 pts higher than a year earlier.

3-year growth-40.1% profit

Revenue compounded at 22.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue341304368207194173237217
Net profit29326-13-6152221
Net margin %8.41.17.0-6.1-3.08.69.49.6
EPS (₹)4.770.645.09-2.49-1.132.944.44.1

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue1233922819666560450508600
Net profit101009246-2-117-13169
Net margin %0.810.811.27.0-0.3-25.9-25.811.6
EPS (₹)1.9619.6518.1711.35-0.48-28.55-32.117.8

3 · The quality

How well does it turn capital into profit?

Return on equity was 0.6% in Mar 2026; debt to equity is 0.19.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %0.67.97.96.7
Return on capital %1.17.88.410.2
EBITDA margin %4.915.216.720.8
Net margin %0.810.510.86.8

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR22.8%22.2%
Profit CAGR-40.1%—
Debt to equity0.19
Interest cover2.2x
Current ratio1.89

4 · The owners

Who holds it, and are they adding?

Promoter holding74.45%

Up 4.61 pts over 8 quarters.

Foreign institutions0.93%

Down 1.6 pts over 8 quarters.

Domestic institutions17.44%

Down 1.55 pts over 8 quarters.

Mutual fund schemes27

+2 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.8469.8469.8469.8469.8469.8469.8474.45+4.61
FII2.532.691.41.561.170.870.810.93-1.6
DII18.9920.119.4319.0419.3920.2520.7517.44-1.55
Public8.647.389.349.579.69.058.617.18-1.46

Mutual fund holdings · Oct 2026

27 schemes hold this stock

25 the month before.

  • Kotak Special Opportunities Fund2.36% of NAV
  • Kotak Consumption Fund1.48% of NAV
  • Kotak Healthcare Fund1.26% of NAV
  • UTI Value Fund1.1% of NAV
  • Kotak MNC Fund1.03% of NAV
  • TATA INDIA INNOVATION FUND0.98% of NAV
  • Bandhan Healthcare Fund0.95% of NAV
  • quant Small Cap Fund0.86% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ORCHPHARMA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ORCHPHARMA

What is the ORCHPHARMA share price?

ORCHPHARMA (ORCHPHARMA) last closed at ₹948.60, down 0.77% on the day. Its 52-week range is ₹482.45 to ₹1,107.20.

What is the market cap of ORCHPHARMA?

ORCHPHARMA has a market capitalisation of about ₹5,721 crore.

How are ORCHPHARMA's latest results?

ORCHPHARMA reported revenue of ₹341 crore for Sep 2026, up 75.8% from a year earlier. Net profit was ₹29 crore. Return on equity was 0.6% in Mar 2026. Promoter holding was 74.45% in Sep 2026, up 4.61 points over 8 quarters.

Who owns ORCHPHARMA?

As of Sep 2026, shareholding was: Promoter 74.45%, FII 0.93%, DII 17.44%, Public 7.18%.

How many mutual funds hold ORCHPHARMA?

27 mutual fund schemes held ORCHPHARMA in October 2026. That compares with 25 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.